Top 5 Drug Type | Count |
---|---|
Small molecule drug | 4 |
Monoclonal antibody | 1 |
Biological products | 1 |
Target |
Mechanism PDE4B inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. JP |
First Approval Date27 Sep 2021 |
Target |
Mechanism EGFR antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. CU |
First Approval Date28 Apr 2005 |
Target |
Mechanism Bacterial DNA gyrase inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. JP |
First Approval Date15 Feb 1984 |
Start Date30 May 2026 |
Sponsor / Collaborator |
Start Date28 Feb 2026 |
Sponsor / Collaborator |
Start Date30 Oct 2025 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Nimotuzumab ( EGFR ) | Glioma More | Approved |
Ciclopirox | Candidiasis More | Approved |
Fluocinolone Acetonide/Neomycin Sulfate ( GR x PBPs ) | Dermatophilosis More | Approved |
Fluocinolone Acetonide ( GR ) | Pruritus More | Approved |
Heptar ( AT III ) | Thrombosis More | Phase 3 |